Adaptive Phage Therapeutics
Latest round
- Series B
Last raised
- May 2023
Total raised
- $55M
Investors
- 3
About Adaptive Phage Therapeutics
Founded in 2016 by Carl Merril MD and Gregory Merril and based in Maryland, US, Adaptive Phage Therapeutics, Inc. operates as a biotechnology company that offers a therapeutic response for patients with multi-drug-resistant (MDR) pathogenic bacteria., a portfolio company of Mirae Asset Global Investments, Deerfield Management, RTW Investments, Nantahala Capital Management, Cystic Fibrosis Foundation, OrbiMed Advisors, and AMR Action Fund, acquired Adaptive Phage Therapeutics, Inc. from Mayo Clinic, Deerfield Management, and AMR Action Fund. The company’s primary product, PhageBank™, addresses this challenge by utilizing an expanding library of bacteriophages, or phages, which offer broad-spectrum and polymicrobial coverage against resistant bacteria. The PhageBank™ phages are selected using a proprietary phage susceptibility assay developed in collaboration with Mayo Clinic Laboratories.
Who invested in Adaptive Phage Therapeutics
3 investors across 3 rounds
See all investors in Adaptive Phage Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Adaptive Phage Therapeutics
Who invested in Adaptive Phage Therapeutics?
Adaptive Phage Therapeutics has 3 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Adaptive Phage Therapeutics raised?
Adaptive Phage Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Adaptive Phage Therapeutics last raise money?
Adaptive Phage Therapeutics's most recent round on record is a Series B, in May 2023.
What does Adaptive Phage Therapeutics do?
Founded in 2016 by Carl Merril MD and Gregory Merril and based in Maryland, US, Adaptive Phage Therapeutics, Inc.
Where is Adaptive Phage Therapeutics headquartered?
Adaptive Phage Therapeutics is headquartered in Gaithersburg, US.
Which VCs invest in companies like Adaptive Phage Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Adaptive Phage Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Adaptive Phage Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.